Pharma News

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for mepolizumab, which will be commercialised under the brand name Nucala, as an add-on treatment for severe refractory eosinophilic asthma in adult patients.

Novo Nordisk announced the headline results from the second phase 3a trial for semaglutide, SUSTAIN3. Semaglutide is a new GLP-1 analogue administered subcutaneously once weekly. The trial investigated the efficacy and safety of 1.0 mg semaglutide compared with 2.0 mg exenatide once-weekly after 56 weeks of treatment added on to 1-2 oral antidiabetic drugs in 813 people with type 2 diabetes.

US Food and Drug Administration (FDA) has approved Novonordisk's Tresiba® and Ryzodeg® 70/30 for the treatment of diabetes mellitus in adults after review of the class II resubmissions of the New Drug Applications (NDAs).

New research shows that taking blood pressure medications at bedtime whilst asleep halves the risk of developing type 2 diabetes. The study is published in Diabetologia.

Researchers have created smarter immune cells that produce and deliver a healing protein to the brain while also teaching neurons to begin making the protein for themselves. The study was published in PLOS One.

[adsense:336x280:8701650588]

Researchers have developed a promising titanium and gold based compound that destroys kidney cancer cells. The findings appeared in the journal Chemical Science.

A new study warns that if you often feel dizzy, faint or light-headed after getting up, these symptoms could indicate greater risk of developing brain disease such as Parkinson's or dementia, and even an increased risk of death. The findings appeared in the online issue of the journal Neurology.

Glioblastoma multiforme (GBM) is the most commonly occurring brain tumor in adults. A new research has now revealed that activating a specific family of proteins may stop the spread of this most lethal and aggressive brain cancer. The study appeared online in Molecular Biology of the Cell.

Impax Laboratories, Inc, a specialty pharmaceutical company, has received US Food and Drug Administration (FDA) approval for generic Mestinon Timespan tablets (pyridostigmine bromide extended release), 180 mg. The company is going for commercialisation of this product.

New research suggests that some, but not all adults who have experienced sexual or physical abuse as children go on to develop long term depression, this could partly be due to their specific genetic make up. Researchers also found that the same gene variant that can make a person sad in one context, can trigger happiness in another context. The research was published in the British Journal of Psychiatry Open.